IntelGenx Technologies Corp.
OTCQX : IGXT
TSX VENTURE : IGX

IntelGenx Technologies Corp.

September 07, 2016 09:52 ET

IntelGenx to Present at the 18th Annual Rodman & Renshaw Global Investment Conference and the 11th Annual Singular Research Conference

SAINT-LAURENT, CANADA--(Marketwired - Sept. 7, 2016) - IntelGenx Corp., (TSX VENTURE:IGX) (OTCQX:IGXT), today announced that Dr. Horst Zerbe, President and Chief Executive Officer, will present at two upcoming conferences. Also present and available for questions will be Andre Godin, Executive Vice-President and Chief Financial Officer.

Rodman & Renshaw 18th Annual Global Investment Conference

Date: Monday, September 12

Location: Lotte New York Palace Hotel, New York City

Presentation Time: 10:50 AM Eastern Time

11th Annual Singular Research Conference "Best of the Uncovereds"

Date: Thursday, September 22

Location: Luxe Sunset Boulevard Hotel, Los Angeles

About IntelGenx:

IntelGenx is a leading oral drug delivery company focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform. Established in 2003, the Montreal-based company is listed on the TSX-V and OTC-QX.

IntelGenx highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx state-of-the art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to our clients. More information is available about the company at: www.intelgenx.com.

Forward Looking Statements:

This document may contain forward-looking information about IntelGenx' operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx' plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx' actual results could differ materially from those expressed or implied by these forward looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx' annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities and www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange), nor the OTCQX accepts responsibility for the adequacy or accuracy of this release.

Source: IntelGenx Technologies Corp.

Contact Information

  • Edward Miller
    Director, IR and Corporate Communications
    IntelGenx Corp.
    +1 514-331-7440 (ext. 217)
    edward@intelgenx.com